Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceGlobeNewsWire • 11/08/23
Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 11/01/23
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBridGlobeNewsWire • 09/28/23
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in AdultsGlobeNewsWire • 09/20/23
Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/02/23
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceGlobeNewsWire • 08/02/23
Vericel: Multiyear Growth Catalysts, Proprietary Solutions Will Drive Market Cap ExpansionSeeking Alpha • 06/28/23
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/10/23
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceGlobeNewsWire • 05/10/23
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D.PRNewsWire • 05/02/23
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023GlobeNewsWire • 02/28/23
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial GuidanceGlobeNewsWire • 02/23/23